Last reviewed · How we verify

Isotonic crystalloids

Marie Kristine Jessen, MD · FDA-approved active Small molecule Under review

Isotonic crystalloids is a Intravenous fluid / Crystalloid solution Small molecule drug developed by Marie Kristine Jessen, MD. It is currently FDA-approved for Hypovolemic shock and acute blood loss resuscitation, Perioperative fluid maintenance and replacement, Dehydration and electrolyte imbalance correction.

Isotonic crystalloids restore intravascular volume and maintain electrolyte balance by providing a physiologically balanced solution of water and electrolytes that distributes across body fluid compartments.

Isotonic crystalloids, also known as 0.9% saline solution, are a type of small molecule modality used in medical treatments. They have been studied in various clinical trials, including those for anesthesia, cancer, and bradycardia, and have been used as interventions in studies such as the comparison of atropine or ephedrine pretreatment for preventing bradycardia in elderly patients.

At a glance

Generic nameIsotonic crystalloids
SponsorMarie Kristine Jessen, MD
Drug classIntravenous fluid / Crystalloid solution
ModalitySmall molecule
Therapeutic areaCritical Care / Emergency Medicine / Perioperative Medicine
PhaseFDA-approved

Mechanism of action

Isotonic crystalloids (such as normal saline 0.9% and lactated Ringer's solution) are intravenous fluids with osmolarity matching plasma, allowing them to equilibrate across the intracellular and extracellular compartments without causing cellular water shifts. They restore circulating volume in hypovolemic states, maintain electrolyte homeostasis, and serve as the first-line fluid resuscitation agent in acute care settings. These solutions do not contain colloids or medications and work purely through volume expansion and osmotic balance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Isotonic crystalloids

What is Isotonic crystalloids?

Isotonic crystalloids is a Intravenous fluid / Crystalloid solution drug developed by Marie Kristine Jessen, MD, indicated for Hypovolemic shock and acute blood loss resuscitation, Perioperative fluid maintenance and replacement, Dehydration and electrolyte imbalance correction.

How does Isotonic crystalloids work?

Isotonic crystalloids restore intravascular volume and maintain electrolyte balance by providing a physiologically balanced solution of water and electrolytes that distributes across body fluid compartments.

What is Isotonic crystalloids used for?

Isotonic crystalloids is indicated for Hypovolemic shock and acute blood loss resuscitation, Perioperative fluid maintenance and replacement, Dehydration and electrolyte imbalance correction, Burn injury fluid resuscitation.

Who makes Isotonic crystalloids?

Isotonic crystalloids is developed and marketed by Marie Kristine Jessen, MD (see full Marie Kristine Jessen, MD pipeline at /company/marie-kristine-jessen-md).

What drug class is Isotonic crystalloids in?

Isotonic crystalloids belongs to the Intravenous fluid / Crystalloid solution class. See all Intravenous fluid / Crystalloid solution drugs at /class/intravenous-fluid-crystalloid-solution.

What development phase is Isotonic crystalloids in?

Isotonic crystalloids is FDA-approved (marketed).

What are the side effects of Isotonic crystalloids?

Common side effects of Isotonic crystalloids include Hyperchloremic acidosis, Fluid overload / pulmonary edema, Hypokalemia, Phlebitis at infusion site.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing